Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Carcinoma × NHS-IL12 immunocytokine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Malignant mesenchymal tumor 1 Carcinoma 1 Breast Neoplasms 1

Interventions

Carboplatin 9 pembrolizumab 8 Paclitaxel 8 Cisplatin 8 Radiotherapy, Intensity-Modulated 6 Magnetic Resonance Spectroscopy 6 fludarabine 4 Specimen Handling 4 Pemetrexed 4 Nivolumab 4 Gemcitabine 4 Cyclophosphamide 4 trebananib 3 osimertinib 3 liposomal doxorubicin 3 Radiotherapy 3 Fluorouracil 3 Docetaxel 3 DNA 3 volociximab 2 poly ICLC 2 lenvatinib 2 fludarabine phosphate 2 Sorafenib 2 Radiosurgery 2 Midazolam 2 Interleukin-2 2 Capecitabine 2 Biopsy 2 Bevacizumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01417546 2021-10-18

NHS-IL12 for Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed

Malignant mesenchymal tumor, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡